Cancer survival rates among the best in the nation.
We’ve got your back in the fight.
*Data source: Surveillance, Epidemiology, and End Results (SEER) 17 registries, National Cancer Institute, 2022. AJCC All Stages, 5 Year Relative Survival. Date of diagnosis from 2012 – 2018.
Clinical Trials and Research Programs
We get better outcomes due to our leadership of clinical trials and research programs.
Clinical trials can provide access to cutting-edge therapies years before they are widely available. We recruit, initiate and conduct early-phase clinical trials and are the Principal Investigator (PI) for multiple clinical trials. In addition, we are the subject-matter experts on many rare cancers—not only are we leading research, we are teaching it. This is where future lifesaving FDA-approved treatments originate.
Our three areas of expertise are laboratory, clinical and behavioral/population-based research.
The CU Cancer Center members are involved in multiple research programs, including:
- Cancer Cell Biology
- Cancer Prevention and Control
- Developmental Therapeutics
- Hormone-Related Malignancies
- Lung, Head and Neck Cancer
- Molecular Oncology
We focus our approach on personalized medicine with the study of human immunology and the practice of immunotherapy, which works by training the immune system to find and kill cancer cells and helping the body produce cancer-fighting immune cells that effectively locate and destroy cancer cells.
NCI Comprehensive Cancer Center
We are the only cancer center in Colorado designated by the National Cancer Institute, and one of 56 in the country.
National Comprehensive Cancer Network
As one of just 33 NCCN cancer centers in the U.S., we write treatment guidelines that have been downloaded more than a million times, create treatment advisory and protocols that most other oncologists and cancer centers follow and diagnose and treat all types of cancer, with a heightened focus on complex, aggressive and uncommon cancers.
Learn more about our survival rates for each type of cancer.
*SEER survival rate is for persons diagnosed between 2013–2019